A behavioral test battery for mouse models of Angelman syndrome: a powerful tool for testing drugs and novel Ube3a mutants.

The study is in mice, not in people with Angelman syndrome, so it does not show what will happen in a clinic. The mouse model carries a Ube3a mutation, while most people with Angelman syndrome have a larger chromosomal deletion that may add other gene effects. Genetic background strongly changed the results: in 129S2 mice most behavioral phenotypes were absent except forced swimming, and in C57BL/6J mice the forced swim result went in the opposite direction. The battery did not include a reliable cognitive test, and the authors note that learning deficits in these mice are mild and hard to detect. Some tests were weak or unstable: open field distance required 21 mice per genotype, and marble burying did not distinguish genotypes when the same mice were retested. Sex affected rotarod performance, so mixed groups need careful matching. Daily minocycline injections produced visible deposits and dullness of the liver, and the paper notes this route is not ideal.

No conflict-of-interest or funding declaration is included in the supplied text; the provided publication types mention research support from non-U.S. government sources.

Do not use this paper to decide whether minocycline or levodopa/carbidopa should be given to a patient. It tested mouse Angelman models, and the human trials mentioned showed no significant improvement in AS patients.